Dexcom Pays PBMs Kickbacks to Exclude Rival CGMs; Senseonics Found a Way Around That

This week (on June 3, 2023), there was an interestingannouncement from the Maryland-based medical device startupSenseonics, Inc. that UnitedHealthcare will begin providing coverage for theEversense E3 CGM System effective July 1, 2023 for people with Type 1 and insulin-requiring Type 2 diabetes. You may recall that Senseonics received a cash-infusion financial lifeline from Ascensia Diabetes Care back on August 10, 2020 (see the news release for that athttps://www.businesswire.com/news/home/20200810005677/en/Senseonics-Announces-Strategic-Collaboration-with-Ascensia-Diabetes-Care for more) when that company effectively paid for its CGM system. Still, Eversense remains comparatively tiny in the CGM space.My loyal readers may also recall that I have complained that Dexcom is paying rebate kickbacks to vertically-integrated (with commercial healthcare insurance companies) Pharmacy Benefit Managers formulary managers to EXCLUDE rival CGM ' s from their prescription drug formularies. Catch Pembroke Consulting ' s President Adam J. Fein of formulary exclusions athttps://www.drugchannels.net/2023/01/the-big-three-pbms-2023-formulary.html for more info. if you ' re interested in reading up on the practice. In essence, he describes the situation this way: " Formulary exclusions have emerged as a powerful tool for PBMs to gain additional negotiating leverage against manufacturers. The prospect of exclusion leads manufacturers to offer deeper rebates to avoid being cut from the formular...
Source: Scott's Web Log - Category: Endocrinology Tags: 2023 Ascensia bribes CGM Eversense Formulary Exclusion kickbacks PBM Senseonics Source Type: blogs